Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia

Phase 2

Completed

• Conditions: Leishmaniasis, Cutaneous; Leishmania Braziliensis Complex; Leishmaniasis, American; Leishmaniasis; American, Cutaneous
• Interventions: Drug: Paromomycin Sulfate; Other: Placebo; Drug: Pentamidine Isethionate

• Registration Number: NCT03096457
• Lead Sponsor: Fundacion Nacional de Dermatologia

Brief Summary

This protocol will compare topical paromomycin to standard intralesional (IL) antimony (Sb) to placebo for L braziliensis in Bolivia.

Detailed Description

Patients will be randomized between Paromomycin cream applied topically once daily for 20 days (group 1--40 patients), pentamidine administered intralesionally at 120 ug/mm2 on days 1, 3, 5 (group 2-20 patients), and cream vehicle applied topically once daily for 20 days (group 3-20 patients).

After treatment, all patients will be followed for 1, 3, and 6 months.

Study Timeline

• Study First Submitted: 2017-03-09
• Study First Submitted QC: 2017-03-24
• Study First Posted: 2017-03-30
• Study Start: 2017-04-15
• Primary Completion: 2018-03-18
• Study Completion: 2018-04-01
• Status Verified: 2018-07
• Last Update Submitted: 2021-02-01
• Last Update Posted: 2021-02-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• Gender: Male or female
• Age: >12 yrs of age
• Presentation: 1-to-2 ulcerative lesions, each < 30 mm in largest diameter and with a total lesion area <900 mm2.
• Parasitology: Parasitological confirmation of the lesion will be made by visualization or culture of Leishmania from the biopsy or aspirate of the lesion.

Exclusion Criteria

• Previous treatment for leishmaniasis with Sb, pentamidine, amphotericin B, miltefosine, imidazoles, allopurinol in the last 3 months.
• Other diseases that would be likely in the PI's opinion to interact, either positively or negatively, with treatment.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group 1 - Paromomycin cream	Paromomycin Sulfate	40 subjects will be included to receive 15% paromomycin in aquafilm base twice a day during 20 consecutive days. The lesion will be cleaned , then, a generous amount of the study drug (an amount sufficient to cover the area of the ulcer and the lesion border) will be applied to the lesion and rubbed into the ulcer using a gloved finger by a member of the clinical study staff. After application of the study drug, the patient will be observed for 15 minutes for signs of adverse events. If there are no signs of local toxicity, the area of the ulcer will be covered with extra study drug. For Days 2-20, the study drug will be applied and the lesion covered with a sterile gauze and tape dressing as on Day 1.
Group 3. Vehicle control	Placebo	10% Urea en parafilm cream will be used in similar ways as paromomycin cream in group 1
Group 2. Local Injectable Pentamidine	Pentamidine Isethionate	20 subjects will be included to receive IL pentamidine \[Pentacarinat® Sanofi-Aventis: 30 mg/ml\] will administered at a dose of 120 ug (4 ul) per mm2 of lesion area 3 times (on days 1, 3, and 5) as per our previous experience. A small button of Xylocaine® will be applied by means of a thin needle at the four cardinal points of the lesion and then a small gauge (23g) needle will introduce the drug in each cardinal point. The needle will be moved in all directions to infiltrate of whole lesion and surrounding infiltrated area.

Primary Outcome Measures

Name	Time	Method
Change of Lesion size	6 months	change of lesion area at 6 months after treatment compared to baseline

Secondary Outcome Measures

Name	Time	Method
Number of participants with treated-related adverse events	1 month	Adverse events will measured according to CTCAE 4.03

Trial Locations

Locations (2)

Hospital Dermatologico de Jorochito; 🇧🇴 Jorochito, SC, Bolivia

Hospital Local Palos Blancos; 🇧🇴 Palos Blancos, La Paz, Bolivia